PL1940447T3 - Leczenie zaburzeń neurodegeneracyjnych - Google Patents
Leczenie zaburzeń neurodegeneracyjnychInfo
- Publication number
- PL1940447T3 PL1940447T3 PL06793581T PL06793581T PL1940447T3 PL 1940447 T3 PL1940447 T3 PL 1940447T3 PL 06793581 T PL06793581 T PL 06793581T PL 06793581 T PL06793581 T PL 06793581T PL 1940447 T3 PL1940447 T3 PL 1940447T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- neurodegenerative disorders
- neurodegenerative
- disorders
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05108946 | 2005-09-28 | ||
| EP06793581.7A EP1940447B1 (en) | 2005-09-28 | 2006-09-18 | Treatment of neurodegenerative disorders |
| PCT/EP2006/066438 WO2007039436A1 (en) | 2005-09-28 | 2006-09-18 | Treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1940447T3 true PL1940447T3 (pl) | 2014-04-30 |
Family
ID=37622051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06793581T PL1940447T3 (pl) | 2005-09-28 | 2006-09-18 | Leczenie zaburzeń neurodegeneracyjnych |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20070072795A1 (pl) |
| EP (1) | EP1940447B1 (pl) |
| JP (1) | JP5096345B2 (pl) |
| KR (1) | KR20080038440A (pl) |
| CN (1) | CN101277715B (pl) |
| AR (1) | AR055654A1 (pl) |
| AU (1) | AU2006298826B2 (pl) |
| BR (1) | BRPI0616572A2 (pl) |
| CA (1) | CA2622609A1 (pl) |
| DK (1) | DK1940447T3 (pl) |
| ES (1) | ES2445035T3 (pl) |
| IL (1) | IL189853A (pl) |
| PL (1) | PL1940447T3 (pl) |
| RU (1) | RU2467761C2 (pl) |
| SI (1) | SI1940447T1 (pl) |
| TW (1) | TWI380824B (pl) |
| WO (1) | WO2007039436A1 (pl) |
| ZA (1) | ZA200802270B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| CL2008002054A1 (es) | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| RU2515914C1 (ru) * | 2013-02-12 | 2014-05-20 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика" | Гибридный белок на основе рекомбинантного эритропоэтина человека, обладающий пролонгированным действием (варианты), и способ его получения |
| RU2561050C2 (ru) * | 2013-08-28 | 2015-08-20 | Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера |
| AR113091A1 (es) * | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US644077A (en) * | 1898-08-01 | 1900-02-27 | Farbenfabriken Of Elberfeld Company | Acetyl salicylic acid. |
| FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) * | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| CA2383940A1 (en) * | 1999-04-13 | 2000-10-19 | The Kenneth S. Warren Laboratories, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US6225895B1 (en) * | 1999-05-26 | 2001-05-01 | Floyd E. Bigelow, Jr. | Towed vehicle monitor system |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| JP3967594B2 (ja) * | 2000-05-15 | 2007-08-29 | エフ．ホフマン−ラ ロシュ アーゲー | 新しい薬剤組成物 |
| JP2004502706A (ja) * | 2000-07-10 | 2004-01-29 | アルバート・ティー・ナイトー | 血液脳関門を開口する方法 |
| DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| DE60144439D1 (de) * | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| CA2488497A1 (en) * | 2002-06-11 | 2003-12-18 | The Burnham Institute | Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| US20040122216A1 (en) * | 2002-07-01 | 2004-06-24 | Jacob Nielsen | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| MXPA05012515A (es) * | 2003-05-19 | 2006-05-25 | Kenneth S Warren Inst Inc | Citocinas protectoras de tejido para la proteccion, restablecimiento y potenciacion de celulas, tejidos y organos sensibles, con una ventana terapeutica ampliada. |
| JP2007514673A (ja) * | 2003-12-19 | 2007-06-07 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用 |
| ATE488519T1 (de) * | 2005-09-28 | 2010-12-15 | Hoffmann La Roche | Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten |
-
2005
- 2005-09-28 US US11/237,505 patent/US20070072795A1/en not_active Abandoned
-
2006
- 2006-09-18 CN CN2006800360941A patent/CN101277715B/zh not_active Expired - Fee Related
- 2006-09-18 RU RU2008116309/15A patent/RU2467761C2/ru not_active IP Right Cessation
- 2006-09-18 AU AU2006298826A patent/AU2006298826B2/en not_active Ceased
- 2006-09-18 EP EP06793581.7A patent/EP1940447B1/en not_active Not-in-force
- 2006-09-18 ES ES06793581.7T patent/ES2445035T3/es active Active
- 2006-09-18 WO PCT/EP2006/066438 patent/WO2007039436A1/en not_active Ceased
- 2006-09-18 CA CA002622609A patent/CA2622609A1/en not_active Abandoned
- 2006-09-18 PL PL06793581T patent/PL1940447T3/pl unknown
- 2006-09-18 DK DK06793581.7T patent/DK1940447T3/da active
- 2006-09-18 BR BRPI0616572-9A patent/BRPI0616572A2/pt not_active Application Discontinuation
- 2006-09-18 SI SI200631739T patent/SI1940447T1/sl unknown
- 2006-09-18 JP JP2008532719A patent/JP5096345B2/ja not_active Expired - Fee Related
- 2006-09-18 KR KR1020087007412A patent/KR20080038440A/ko not_active Ceased
- 2006-09-25 TW TW095135363A patent/TWI380824B/zh not_active IP Right Cessation
- 2006-09-26 AR ARP060104198A patent/AR055654A1/es not_active Application Discontinuation
-
2008
- 2008-02-28 IL IL189853A patent/IL189853A/en not_active IP Right Cessation
- 2008-03-10 ZA ZA200802270A patent/ZA200802270B/xx unknown
- 2008-09-19 US US12/284,277 patent/US20100267632A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0616572A2 (pt) | 2009-11-24 |
| CA2622609A1 (en) | 2007-04-12 |
| CN101277715B (zh) | 2013-03-27 |
| AR055654A1 (es) | 2007-08-29 |
| DK1940447T3 (da) | 2014-01-20 |
| AU2006298826A1 (en) | 2007-04-12 |
| ES2445035T3 (es) | 2014-02-27 |
| EP1940447A1 (en) | 2008-07-09 |
| AU2006298826B2 (en) | 2010-04-01 |
| TWI380824B (zh) | 2013-01-01 |
| US20100267632A1 (en) | 2010-10-21 |
| SI1940447T1 (sl) | 2014-03-31 |
| WO2007039436A1 (en) | 2007-04-12 |
| IL189853A0 (en) | 2008-11-03 |
| KR20080038440A (ko) | 2008-05-06 |
| JP5096345B2 (ja) | 2012-12-12 |
| CN101277715A (zh) | 2008-10-01 |
| JP2009510008A (ja) | 2009-03-12 |
| ZA200802270B (en) | 2009-02-25 |
| US20070072795A1 (en) | 2007-03-29 |
| RU2008116309A (ru) | 2009-11-10 |
| EP1940447B1 (en) | 2013-11-27 |
| IL189853A (en) | 2012-06-28 |
| RU2467761C2 (ru) | 2012-11-27 |
| TW200727911A (en) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| IL185052A0 (en) | Treatment of bone disorders | |
| IL188204A0 (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
| IL191283A (en) | Compositions for treating eye irregularities | |
| ZA200809528B (en) | Treatment for depressive disorders | |
| EP2004204A4 (en) | TREATMENT OF NEURODEGENERATIVE DISEASES | |
| IL190920A0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA200809527B (en) | Treatment for depressive disorders | |
| PL1890684T3 (pl) | Leczenie zaburzeń snu i czuwania | |
| ZA200801667B (en) | Novel pharmaceutical combinations for the treatment of respiratory disorders | |
| ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| IL187439A0 (en) | Compounds useful for treating neurodegenerative disorders | |
| IL198856A0 (en) | Compounds useful for treating neurodegenerative disorders | |
| EP1859277A4 (en) | TREATMENT OF NEUROLOGICAL DISORDERS | |
| IL193799A0 (en) | New therapeutic combinations for the treatment or prevention of psycotic disorders | |
| IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| PL1982178T3 (pl) | Sposoby leczenia zaburzeń afektywnych | |
| ZA200805108B (en) | Treatment of neurodegenerative disorders | |
| ZA200802270B (en) | Treatment of neurodegenerative disorders | |
| GB0809476D0 (en) | Treatment of neurodegenerative disorders | |
| GB0610183D0 (en) | Treatment of neurodegenerative diseases | |
| IL177955A0 (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| IL190182A0 (en) | 2-aminoalcohols for the treatment of neurodegenerative diseases | |
| ZA200807678B (en) | Meridamycin analogues for the treatment of neurodegenerative disorders | |
| GB0410846D0 (en) | Treatment of neurodegenerative conditions |